{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:24:38Z","timestamp":1787617478313,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":96,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-49012-1","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:55:02Z","timestamp":1779368102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["RRM2 as a biomarker and therapeutic target in letrozole resistant estrogen receptor positive breast cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Wan-Yu","family":"Hung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shou-Tung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hon","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Breast Cancer Genomics and Therapy Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"49012_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold, M. et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast 66, 15\u201323 (2022).","journal-title":"Breast"},{"issue":"1","key":"49012_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10549-020-05746-8","volume":"183","author":"V Walter","year":"2020","unstructured":"Walter, V. et al. Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer. Breast Cancer Res. Treat. 183(1), 137\u2013144 (2020).","journal-title":"Breast Cancer Res. Treat."},{"issue":"7","key":"49012_CR3","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ctrv.2014.03.004","volume":"40","author":"EM Ciruelos Gil","year":"2014","unstructured":"Ciruelos Gil, E. M. Targeting the PI3K\/AKT\/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat. Rev. 40(7), 862\u2013871 (2014).","journal-title":"Cancer Treat. Rev."},{"key":"49012_CR4","doi-asserted-by":"publisher","first-page":"4736091","DOI":"10.1155\/2020\/4736091","volume":"2020","author":"N Tuasha","year":"2020","unstructured":"Tuasha, N. & Petros, B. Heterogeneity of tumors in breast cancer: Implications and prospects for prognosis and therapeutics. Scientifica 2020, 4736091. https:\/\/doi.org\/10.1155\/2020\/4736091 (2020).","journal-title":"Scientifica"},{"issue":"7","key":"49012_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1093\/hmg\/10.7.705","volume":"10","author":"PL Welcsh","year":"2001","unstructured":"Welcsh, P. L. & King, M. C. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum. Mol. Genet. 10(7), 705\u2013713 (2001).","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"49012_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/gm326","volume":"4","author":"YY Li","year":"2012","unstructured":"Li, Y. Y. & Jones, S. J. Drug repositioning for personalized medicine. Genome Med. 4(3), 27. https:\/\/doi.org\/10.1186\/gm326 (2012).","journal-title":"Genome Med."},{"issue":"5","key":"49012_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.molmed.2011.01.007","volume":"17","author":"Y He","year":"2011","unstructured":"He, Y., Hoskins, J. M. & McLeod, H. L. Copy number variants in pharmacogenetic genes. Trends Mol. Med. 17(5), 244\u2013251 (2011).","journal-title":"Trends Mol. Med."},{"issue":"3","key":"49012_CR8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1124\/dmd.119.089680","volume":"48","author":"L Her","year":"2020","unstructured":"Her, L. & Zhu, H. J. Carboxylesterase 1 and precision pharmacotherapy: Pharmacogenetics and nongenetic regulators. Drug Metab. Dispos. 48(3), 230\u2013244 (2020).","journal-title":"Drug Metab. Dispos."},{"issue":"19","key":"49012_CR9","doi-asserted-by":"publisher","first-page":"4689","DOI":"10.3390\/cancers15194689","volume":"15","author":"P Miziak","year":"2023","unstructured":"Miziak, P. et al. Estrogen receptor signaling in breast cancer. Cancers (Basel) 15(19), 4689. https:\/\/doi.org\/10.3390\/cancers15194689 (2023).","journal-title":"Cancers (Basel)"},{"issue":"Suppl 1(Suppl 1","key":"49012_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10549-007-9700-y","volume":"105","author":"D Koeberle","year":"2007","unstructured":"Koeberle, D. & Thuerlimann, B. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. Breast Cancer Res. Treat. 105(Suppl 1(Suppl 1)), 55\u201366 (2007).","journal-title":"Breast Cancer Res. Treat."},{"issue":"Suppl 1(Suppl 1","key":"49012_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s10549-007-9696-3","volume":"105","author":"AS Bhatnagar","year":"2007","unstructured":"Bhatnagar, A. S. The discovery and mechanism of action of letrozole. Breast Cancer Res. Treat. 105(Suppl 1(Suppl 1)), 7\u201317 (2007).","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"49012_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41598-021-84999-9","volume":"11","author":"SH Sim","year":"2021","unstructured":"Sim, S. H., Yang, H. N., Jeon, S. Y., Lee, K. S. & Park, I. H. Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer. Sci. Rep. 11(1), 55\u201366 (2021).","journal-title":"Sci. Rep."},{"issue":"11","key":"49012_CR13","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1210\/me.2011-1314","volume":"26","author":"EF Need","year":"2012","unstructured":"Need, E. F. et al. Research resource: Interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor \u03b1 in luminal breast cancer cells. Mol. Endocrinol. 26(11), 1941\u20131952 (2012).","journal-title":"Mol. Endocrinol."},{"issue":"1","key":"49012_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5493\/wjem.v8.i1.1","volume":"8","author":"D Mosly","year":"2018","unstructured":"Mosly, D., Turnbull, A., Sims, A., Ward, C. & Langdon, S. Predictive markers of endocrine response in breast cancer. World J. Exp. Med. 8(1), 1\u20137 (2018).","journal-title":"World J. Exp. Med."},{"issue":"4","key":"49012_CR15","first-page":"575","volume":"19","author":"S van Dam","year":"2018","unstructured":"van Dam, S., V\u00f5sa, U., van der Graaf, A., Franke, L. & de Magalh\u00e3es, J. P. Gene coexpression analysis for functional classification and gene-disease predictions. Brief Bioinform. 19(4), 575\u2013592 (2018).","journal-title":"Brief Bioinform."},{"issue":"11","key":"49012_CR16","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.celrep.2015.08.014","volume":"12","author":"BN Kholodenko","year":"2015","unstructured":"Kholodenko, B. N. Drug resistance resulting from kinase dimerization is rationalized by thermodynamic factors describing allosteric inhibitor effects. Cell Rep. 12(11), 1939\u20131949 (2015).","journal-title":"Cell Rep."},{"key":"49012_CR17","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nprot.2016.051","volume":"11","author":"S Forli","year":"2016","unstructured":"Forli, S. et al. Computational protein\u2013ligand docking and virtual drug screening with the AutoDock suite. Nat. Protoc. 11, 905\u2013919 (2016).","journal-title":"Nat. Protoc."},{"issue":"4","key":"49012_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","volume":"37","author":"AB Hanker","year":"2020","unstructured":"Hanker, A. B., Sudhan, D. R. & Arteaga, C. L. Overcoming endocrine resistance in breast cancer. Cancer Cell 37(4), 496\u2013513 (2020).","journal-title":"Cancer Cell"},{"issue":"3","key":"49012_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0165-6147(03)00026-9","volume":"24","author":"ZA Stewart","year":"2003","unstructured":"Stewart, Z. A., Westfall, M. D. & Pietenpol, J. A. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol. Sci. 24(3), 139\u2013145 (2003).","journal-title":"Trends Pharmacol. Sci."},{"issue":"15","key":"49012_CR20","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1080\/15384101.2018.1502567","volume":"17","author":"KL Thu","year":"2018","unstructured":"Thu, K. L., Soria-Bretones, I., Mak, T. W. & Cescon, D. W. Targeting the cell cycle in breast cancer: Toward the next phase. Cell Cycle 17(15), 1871\u20131885 (2018).","journal-title":"Cell Cycle"},{"issue":"1","key":"49012_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13046-016-0433-9","volume":"35","author":"R Visconti","year":"2016","unstructured":"Visconti, R., Della Monica, R. & Grieco, D. Cell cycle checkpoint in cancer: A therapeutically targetable double-edged sword. J. Exp. Clin. Cancer Res. 35(1), 153 (2016).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1-5","key":"49012_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jsbmb.2006.09.028","volume":"102","author":"CM McNeil","year":"2006","unstructured":"McNeil, C. M. et al. c-Myc overexpression and endocrine resistance in breast cancer. J. Steroid Biochem. Mol. Biol. 102(1\u20135), 147\u2013155 (2006).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"45","key":"49012_CR23","doi-asserted-by":"publisher","first-page":"27736","DOI":"10.18632\/oncotarget.25552","volume":"9","author":"K Petrossian","year":"2018","unstructured":"Petrossian, K. et al. ER\u03b1-mediated cell cycle progression is an important requisite for CDK4\/6 inhibitor response in HR+ breast cancer. Oncotarget 9(45), 27736\u201327751 (2018).","journal-title":"Oncotarget"},{"issue":"4","key":"49012_CR24","first-page":"3349","volume":"19","author":"S Zhuang","year":"2020","unstructured":"Zhuang, S., Li, L., Zang, Y., Li, G. & Wang, F. RRM2 elicits the metastatic potential of breast cancer cells by regulating cell invasion, migration and VEGF expression via the PI3K\/AKT signaling. Oncol. Lett. 19(4), 3349\u20133355 (2020).","journal-title":"Oncol. Lett."},{"issue":"12","key":"49012_CR25","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.3390\/cancers14122938","volume":"14","author":"Z Zhou","year":"2022","unstructured":"Zhou, Z., Song, Q., Yang, Y., Wang, L. & Wu, Z. Comprehensive landscape of RRM2 with immune infiltration in pan-cancer. Cancers (Basel) 14(12), 2938 (2022).","journal-title":"Cancers (Basel)"},{"issue":"7","key":"49012_CR26","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/s44318-024-00048-x","volume":"43","author":"L Mei\u00dfner","year":"2024","unstructured":"Mei\u00dfner, L., Niese, L., Sch\u00fcring, I., Mitra, A. & Diez, S. Human kinesin-5 KIF11 drives the helical motion of anti-parallel and parallel microtubules around each other. EMBO J. 43(7), 1244\u20131256 (2024).","journal-title":"EMBO J."},{"issue":"9","key":"49012_CR27","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1111\/febs.15634","volume":"288","author":"XH Li","year":"2021","unstructured":"Li, X. H. et al. PRC1 is a critical regulator for anaphase spindle midzone assembly and cytokinesis in mouse oocyte meiosis. FEBS J. 288(9), 3055\u20133067 (2021).","journal-title":"FEBS J."},{"issue":"5","key":"49012_CR28","doi-asserted-by":"publisher","first-page":"805","DOI":"10.33594\/000000174","volume":"53","author":"Y Jeong","year":"2019","unstructured":"Jeong, Y. et al. EGFR is a therapeutic target in hormone receptor-positive breast cancer. Cell Physiol. Biochem. 53(5), 805\u2013819 (2019).","journal-title":"Cell Physiol. Biochem."},{"key":"49012_CR29","doi-asserted-by":"publisher","first-page":"101103","DOI":"10.1016\/j.drup.2024.101103","volume":"76","author":"A Glaviano","year":"2024","unstructured":"Glaviano, A. et al. Mechanisms of sensitivity and resistance to CDK4\/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. Drug Resist. Updat. 76, 101103. https:\/\/doi.org\/10.1016\/j.drup.2024.101103 (2024).","journal-title":"Drug Resist. Updat."},{"key":"49012_CR30","doi-asserted-by":"publisher","unstructured":"Miller, T.W. Endocrine resistance: what do we know?. Am. Soc. Clin. Oncol. Educ. Book. (2013). https:\/\/doi.org\/10.14694\/EdBook_AM.2013.33.e37","DOI":"10.14694\/EdBook_AM.2013.33.e37"},{"key":"49012_CR31","doi-asserted-by":"publisher","first-page":"101633","DOI":"10.1016\/j.bbrep.2023.101633","volume":"37","author":"N Sadat Kalaki","year":"2024","unstructured":"Sadat Kalaki, N. et al. Systems biology approach to identify biomarkers and therapeutic targets for colorectal cancer. Biochem. Biophys. Rep. 37, 101633. https:\/\/doi.org\/10.1016\/j.bbrep.2023.101633 (2024).","journal-title":"Biochem. Biophys. Rep."},{"issue":"1","key":"49012_CR32","doi-asserted-by":"publisher","first-page":"21246","DOI":"10.1038\/s41598-020-78126-3","volume":"10","author":"KL Sheng","year":"2020","unstructured":"Sheng, K. L. et al. An integrated approach to biomarker discovery reveals gene signatures highly predictive of cancer progression. Sci. Rep. 10(1), 21246 (2020).","journal-title":"Sci. Rep."},{"issue":"8","key":"49012_CR33","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1158\/0008-5472.CAN-07-5873","volume":"68","author":"X Xu","year":"2008","unstructured":"Xu, X. et al. Broad overexpression of ribonucleotide reductase genes in mice specifically induces lung neoplasms. Cancer Res. 68(8), 2652\u20132660 (2008).","journal-title":"Cancer Res."},{"issue":"23","key":"49012_CR34","doi-asserted-by":"publisher","first-page":"17747","DOI":"10.1074\/jbc.M000799200","volume":"275","author":"A Chabes","year":"2000","unstructured":"Chabes, A. & Thelander, L. Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks. J. Biol. Chem. 275(23), 17747\u201317753 (2000).","journal-title":"J. Biol. Chem."},{"key":"49012_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2021.05.035","volume":"154","author":"Y Yuan","year":"2021","unstructured":"Yuan, Y. et al. Phase I\/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer. Eur. J. Cancer 154, 11\u201320 (2021).","journal-title":"Eur. J. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49012-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49012-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49012-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:51:53Z","timestamp":1787615513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49012-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["49012"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-49012-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6183643\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"8 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All data used in this study were obtained from publicly available datasets (GSE20181 and GSE41994) in the Gene Expression Omnibus (GEO) database. These datasets were originally approved by the respective ethics committees of the primary studies. Since this research involves secondary analysis of de-identified, publicly available data, no additional ethical approval or participant consent was required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent for publication is not applicable, as this manuscript does not include any individual person\u2019s data in any form (e.g., identifiable images or personal details).","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26616"}}